United States - English - NLM (National Library of Medicine)

proficient rx lp - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: pharyngitis/tonsillitis caused by streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. uncomplicated skin and skin structure infections due to staphylococcus aureus, streptococcus pyogenes, or streptococcus agalactiae. abscesses usually require surgical drainage. urethritis and cervicitis due to chlamydia tr

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets usp and other antibacterial drugs, azithromycin tablets usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. azithromycin tablets usp are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration ( 2)]. - acute bacterial exacerbations of chronic bronchitis due to

United States - English - NLM (National Library of Medicine)

apotex corp. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin 500 mg in 10 ml - azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. as recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see dosage and administration for dosing recommendations. community-acquired pneumonia due to chlamydia pneumoniae, haemophilus influenzae, legionella pneumophila, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus, or streptococcus pneumoniae in patients who require initial intravenous therapy. pelvic inflammatory disease due to chlamydia trachomatis, neisseria gonorrhoeae, or mycoplasma hominis in patients who require initial intravenous therapy. if anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with a

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin for oral suspension is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration ( 2)]. - acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate for oral therapy. - pharyngitis/tonsillitis caused by streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. - uncomplicated skin and skin structure

United States - English - NLM (National Library of Medicine)

proficient rx lp - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin for oral suspension usp is indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe il

United States - English - NLM (National Library of Medicine)

mckesson corporation - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, usp are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus   influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus   influenzae, moraxella catarrhalis or streptococcus pneumoniae. community-acquired pneumonia due to chlamydia pneumoniae, haemophilus   influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness

United States - English - NLM (National Library of Medicine)

direct rx - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin for oral suspension usp is indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. adults acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illne

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 100 mg in 5 ml - azithromycin for oral suspension is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration ( 2)]. - acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate for oral therapy. - pharyngitis/tonsillitis caused by streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. - uncomplicated skin and skin structure

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see dosage and administration (2)] - acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis. or streptococcus pneumoniae . - community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate for oral therapy. - pharyngitis/tonsillitis caused by streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. - uncomplicated skin and ski

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 500 mg in 5 ml - azithromycin for injection, usp is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. due to chlamydophila pneumoniae , haemophilus influenzae , legionella pneumophila , moraxella catarrhalis , mycoplasma pneumoniae , staphylococcus aureus , or streptococcus pneumoniae in patients who require initial intravenous therapy. due to chlamydia trachomatis , neisseria gonorrhoeae , or mycoplasma hominis in patients who require initial intravenous therapy. if anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with azithromycin. azithromycin for injection, usp should be followed by azithromycin by the oral route as required. [see dosage and administration (2)] to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial